Skip to main content
Premium Trial:

Request an Annual Quote

Schering-Plough to Use MorphoSys HuCAL GOLD Technology

NEW YORK, May 17 (GenomeWeb News) - MorphoSys today said that Schering-Plough will use its HuCAL GOLD technology for two years. 


Terms of the deal, which can be extended for an additional three years, call for the drug maker to use the technology for drug-discovery programs at the firm's Palo Alto, Calif., research site. The contract also provides Schering-Plough with the option to develop HuCAL-derived therapeutic antibodies against up to 10 disease-related targets. 


In return, MorphoSys will receive an upfront payment, annual user fees, and optional R&D funding.


For therapeutic antibody projects undertaken by Schering-Plough, MorphoSys is eligible to receive license and milestone payments related to the successful advancement of projects in clinical development, and royalties on HuCAL antibodies developed under the agreement.


Further financial details were not disclosed.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.